louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06129370: Testing of Medication Dosing Software
Official title: Testing of a Medication Dosing Software for Pediatric Emergency Care
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pediatric Emergency Medicine
Keywords: Simulation
Pediatric emergency care
Healthcare professionals
Medication errors
Lead sponsor: Nura Medical
Sponsor class: INDUSTRY
First posted: 2023-11-13
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The goal of this clinical study is to evaluate the clinical efficiency of a medication dosing software in simulated pediatric emergency care. The main questions it aims to answer are:

* Will the time to patient be significantly reduced with the medication dosage software when compared to standard clinical practice?
* Will the time to calculate dosage of medications be significantly reduced with the medication dosage software when compared to standard clinical practice?
* How will users perceive clinical efficiency, ease of use, confidence level of using the medication dosage software when compared to standard clinical practice?
* How will accuracy of medication dose and volume calculations as well as final volume ready for administration using the medication dosage software compared to standard clinical practice?
* Will the time spent calculating medication doses by the second healthcare professional on pediatric non-acute and acute care cases be significantly reduced with the medication dosage software when compared to standard clinical practice?

Participants will be presented pediatric care scenarios and asked to calculate and prepare intravenous medications under two interventions: the medication dosage software and standard clinical practice (Lexicomp and manual calculator).


Eligibility criteria: Inclusion Criteria:

-Healthcare professionals who have worked or who are currently working at a healthcare facility and involved in the calculation or preparation of IV medication.

Exclusion Criteria:

* Healthcare professionals who cannot read, speak, or understand English or French as the simulations will be conducted in English or French.
* Performance of physically strenuous activity 30 min prior to study.
* Physical limitations that affect performance on required tasks (e.g., inability to place arm cuff on mannequin's arm, inability to handle weight estimation and touchscreen devices).

Primary outcomes:
measure: TIme to patient
timeFrame: Through study completion, up to 3 months
measure: Time to calculate
timeFrame: Through study completion, up to 3 months
Secondary outcomes:
measure: Feedback
timeFrame: Through study completion, up to 3 months
measure: Accuracy
timeFrame: Through study completion, up to 3 months
measure: Time of calculation by second healthcare professional
timeFrame: Through study completion, up to 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01509170: The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia
Official title: Observational Cohort Study- The Clinical and Laboratory Characteristics of Recurrent Drug- Related
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hyponatremia
SIADH
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2012-01-12
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consequtive patients hospitalized to the internal medicine ward due to hyponatremia

Brief summary: The aim of this study is to identify factors associated with hyponatremia among patients hospitalized in the internal medicine ward. Consequtive patients hospitalized because of hyponatremia will be recruited. Follow up will include clinical factors such as background diseases, complete drug history, blood tests including Biochemistry tests (Sodium, renal function), endocrinological evaluation, thyroid function tests, cortisol,urinary sodium on addmition. One month following discharge follow up Sodium level will be taken.


Eligibility criteria: Inclusion Criteria:

* patients hospitalized to the internal medicine ward due to hyponatremia

Exclusion Criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah- Hebrew-University Medical Center
city: Jerusalem
country: Israel
facility: Hadassah-Hebrew University Medical Center
Study officials:
affiliation: Hadassah Medical Organization
name: Mordechai Muszkat, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00881270: Dermacyd Infantile - Acceptability.
Official title: Safety Dermatological Evaluation: Acceptability With Paediatric Follow up Dermacyd Infantile (Lactic Acid).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hygiene
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2009-04-15
Enrollment: 31
Sex: ALL
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Primary Objective:

To prove the safety of the formulation in normal conditions of use.


Eligibility criteria: Inclusion criteria:

* Integral skin test in the region
* Use the same category of cosmetics
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time.

Exclusion criteria:

* Use of Anti-inflammatory, immunosuppressant or anti-histaminic drugs
* Allergic or atopic history to cosmetics products
* Cutaneous active disease (local or general) in the evaluated area
* Disease which can cause immunosuppressant, such as diabetes, HIV
* Endocrine pathology
* Intensive solar exposure until 15 days before evaluation
* Treatment four months before selection.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction.
timeFrame: From the treatment start to the end of the study
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Jaderson Lima
role: STUDY_DIRECTOR
References:
Clinical trial NCT07000370: Bridging Generations: Educating Children on Dementia and Fall Prevention Through Animation
Official title: Bridging Generations: Educating Children on Dementia and Fall Prevention Through Animation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fall Prevention in Healthy Aging
Keywords: fall
Lead sponsor: Northumbria University
Sponsor class: OTHER
First posted: 2025-06-02
Enrollment: 60
Sex: ALL
Minimum age (years): 8
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: students who were studying in primary school

Brief summary: A retrospective data review was conducted on a case-control trial involving 60 children (29 boys, 31 girls) as part of a public education initiative hosted on the web-based platform "Hand in Hand Across Barriers - Public Education Platform" (Facebook).

Detailed description: The program consisted of short, age-appropriate animated narratives reflecting three Home-FAST domains: (1) Home Environment and Furniture, (2) Capability in Activities of Daily Living, and (3) Use of Devices. Pre- and post-intervention assessments included knowledge quizzes and caregiver-supported completion of the 74-item pictorial HSSAT v.5 checklist.

Eligibility criteria: Inclusion Criteria:

* full time students

Exclusion Criteria:

* know neurological disorder

Primary outcomes:
measure: HSSAT (v.5)
timeFrame: 20mins
Secondary outcomes:
Other outcomes:
Locations:
city: Newcastle
country: United Kingdom
facility: Northumbria University
Study officials:
affiliation: Northumbria University
name: Frank Lai, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02702570: Committed Actions for Successful Aging
Official title: Committed Actions for Successful Aging
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Brain Aging
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2016-03-08
Enrollment: 10
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The investigators are planning to recruit approximately 30 study participants aged 50 years and older that will undergo a 4 week attention and emotion regulation intervention. The intervention systematically targets thoughts, emotions and behavior in order to promote quality of life and advance successful brain aging. The investigators will assess the feasibility of recruiting and retaining participants for an attention and emotion regulation intervention. In addition, the investigators will determine the efficacy of the intervention to enhance and promote quality of life, sustained attention, emotions, motivation and cognitive health.

Detailed description: The CASA model is developed here in the investigators program (Geda et al) based on neuroscience and Acceptance and Commitment Therapy (ACT). The rationale for the study is that the cortico-cortical network linking the prefrontal cortex with the mesial temporal lobe is susceptible to the wear and tear of day to day life such as stress and emotional distress. The investigators hypothesize that the CASA intervention will promote emotional and cognitive health by targeting this network.

Eligibility criteria: Participants will be recruited from the community via advertisement in retirement communities, church, and other social gatherings. Eligible participants are cognitively normal males and females aged 50 years and older.

Inclusion criteria:

* Subject will sign approved consent form
* Male or female adults (age \> 50 years of age)
* Subject will complete all of the testing and procedures

Exclusion criteria:

* Refusal to sign the approved consent form
* Refusal to complete all testing and procedures of the study
* Males and females \< age of 50 years

Primary outcomes:
measure: WHOQOL-BREF quality of life questionnaire
timeFrame: Baseline, one year
Secondary outcomes:
measure: Perceived Stress Scale
timeFrame: Baseline, one year
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
Study officials:
affiliation: Mayo Clinic
name: Yonas E Geda, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01836770: Epidural Contrast Flow Patterns of TESI Using the Inferior-Anterior Position as the Final Needle Tip Position.
Official title: Epidural Contrast Flow Patterns of Transforaminal Epidural Steroid Injections Using the Inferior-Anterior Position as the Final Needle Tip Position.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Lumbosacral Radiculopathy
Lumbar Herniated Nucleus Pulposus
Keywords: Transforaminal Epidural Steroid Injections
Lead sponsor: George Washington University
Sponsor class: OTHER
First posted: 2013-04-22
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: George Washington Spine and Pain Center patients.

Brief summary: The purpose of this study is to describe the contrast flow patterns in the epidural space using the inferior-anterior approach with continuous fluoroscopic guidance, and determine how well this approach correlates with appropriate contrast flow patterns and with analgesia at follow up. This knowledge may prove useful in guiding physician practice patterns in the non-surgical management of low back pain.

Hypothesis: The investigators hypothesize that there will be suitable (ventral/anterior) epidural contrast spread based on inferior-anterior needle-tip position, particularly with appropriate needle tip position.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* History of lumbosacral radiculopathy or lumbar herniated nucleus pulposus
* Scheduled for TFESI at GW Spine and Pain Center

Exclusion Criteria:

* Pregnant or plan on becoming pregnant
* Have undergone TFESI in the past year
* Opioid habituation
* Lumbo-sacral stenosis
* Lumbar surgery
* Lumbar spondylolisthesis

Primary outcomes:
measure: Contrast flow patterns
timeFrame: 3 Months
Secondary outcomes:
measure: VAS pain score
timeFrame: 3 months
Other outcomes:
Locations:
city: Washington
country: United States
facility: George Washington Spine and Pain Center
state: District of Columbia
Study officials:
affiliation: George Washington Spine and Pain Center
name: Mehul J Desai, MD MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00790270: Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial
Official title: Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cervical Strain
Keywords: Cervical strain
whiplash
ibuprofen
cyclobenzaprine
Lead sponsor: Stony Brook University
Sponsor class: OTHER
First posted: 2008-11-13
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see whether the combination of a muscle relaxant and anti-inflammatory drug is more effective at relieving pain in patients with neck strains or whiplash than either of the two medications alone.

Detailed description: Muscle relaxants have been used extensively for neck and back pain since muscle spasm is thought to play a role in the cycle of pain and spasm. However, prior studies have conflicting results regarding their additive effect when given in addition to analgesics such as the NSAIDs. Because they have the potential to lead to adverse events their efficacy should be clearly demonstrated before their routine use.

Eligibility criteria: Inclusion Criteria:

* neck pain within 24 hours of injury

Exclusion Criteria:

* Children, allergy or contraindication to any of the study drugs

Primary outcomes:
measure: Pain
timeFrame: Daily for 1 week
measure: Use of Rescue Medications
timeFrame: 24 hours
Secondary outcomes:
measure: Time to Resumption of Work
timeFrame: 1 week
measure: Resumption of Work or School
timeFrame: next day
Other outcomes:
Locations:
city: Stony Brook
country: United States
facility: Stony Brook University
state: New York
Study officials:
affiliation: Stony Brook University
name: adam singer, md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01410370: Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases
Official title: Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy for the Treatment of Patients With Brain Metastases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Brain Metastases
Keywords: Endostar
Radiotherapy
Brain Metastases
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: The First People's Hospital of Lianyungang
First posted: 2011-08-05
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the clinical efficacy and safety of continuous Endostar infusion combined with radiotherapy for treatment of brain metastases.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed malignancy with presence of intraparenchymal brain metastases
* Karnofsky performance status ≥ 40
* Measurable disease according to RECIST criteria
* Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L
* Renal function: Cr ≤ 2.0×ULN
* Hepatic function: BIL ≤ 2.0×ULN, ALT/AST ≤ 5.0×ULN
* Adequate cardiac function
* Life expectancy ≥ 3 months

Exclusion Criteria:

* Evidence of bleeding diathesis or serious infection
* Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension)
* Uncontrollable mental and nervous disorders
* Pregnant or lactating women

Primary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: 1 month after initial treatment
Secondary outcomes:
measure: Overall Survival
timeFrame: 2 year
measure: Serum VEGF Levels
timeFrame: at baseline and 1 month after initial treatment
measure: VEGF levels in tumor tissue
timeFrame: at baseline and 1 month after initial treatment
measure: Incidence of Adverse Events
timeFrame: up to 1 month after last dose
measure: Cerebral Edema
timeFrame: 1 month after initial treatment
Other outcomes:
Locations:
city: Lianyungang
country: China
facility: The First People's Hospital of Lianyungang
state: Jiangsu
Study officials:
affiliation: The First People's Hospital of Lianyungang
name: Xiaodong Jiang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01519570: Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates
Official title: Use of an Electronic Medical Record to Improve Standard Practice in the Primary Care Setting: A Randomized-Controlled Study of Herpes Zoster Vaccination Rates
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Herpes Zoster Disease
Keywords: Herpes Zoster vaccine
Electronic patient portal
Electronic medical record
Primary care
Immunizations
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2012-01-27
Enrollment: 2589
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Despite the significant benefits of herpes zoster vaccine (HZV), vaccination rates remain low. Electronic medical records (EMR) can serve as a practical strategy to better facilitate the application of preventative health care, such as increasing immunization rates. A new care model that can increase the herpes zoster vaccination rate, as well as other preventative health services, is warranted. The objective of this study is to investigate if the functions of an EMR, in combination with a pharmacist as part of the care team, can improve the herpes zoster vaccination rate.


Eligibility criteria: Inclusion Criteria:

* Greater than 60 years of age

Exclusion Criteria:

* Documented herpes zoster vaccine in the EMR

Primary outcomes:
measure: Number of Participants Who Received the Herpes Zoster Vaccine
timeFrame: 6 months
Secondary outcomes:
measure: Difference in Vaccination Rates Between Patients Who Recieved a Mailed Letter Versus a Secure Email
timeFrame: 6 months
measure: Amount of Time Required by a Clinical Pharmacist to Manage This Workflow
timeFrame: 6 months
Other outcomes:
Locations:
city: Columbus
country: United States
facility: The Ohio State University Martha Morehouse General Internal Medicine Clinic
state: Ohio
Study officials:
affiliation: Ohio State University
name: Stuart J Beatty, PharmD
role: PRINCIPAL_INVESTIGATOR
affiliation: The Ohio State Univeristy
name: Shelley H Otsuka, PharmD
role: STUDY_CHAIR
affiliation: Ohio State University
name: Neeraj H Tayal, MD
role: STUDY_CHAIR
affiliation: Ohio State University
name: Kyle Porter, MAS
role: STUDY_CHAIR
affiliation: Ohio State University
name: Peter J Embi, MD, MS
role: STUDY_CHAIR
References:
Clinical trial NCT04360070: The Application of Ketamine for Sedation in Patients With Cardiac Arrest - - KetCat (KETamine in Cardiac ArresT) Study
Official title: The Application of Ketamine for Sedation in Patients With Cardiac Arrest: Feasibility, Safety, and Potential Impact on Neurological Outcomes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiac Arrest, Out-Of-Hospital
Ketamine
Neurologic Manifestations
Keywords: Pilot Study
Single-Centre
Lead sponsor: Fraser Health
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 24
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Recent evidence suggests ketamine may attenuate harmful cellular cascades taking place after brain injury that result in permanent damage. The investigators are interested in researching the application of this in the setting of cardiac arrest. Following cardiac arrest, the brain is deprived oxygen for a period of time, leading to the imitation of these harmful cellular processes. The investigators hypothesize that patients who receive ketamine as part of their standard sedation procedures during cardiac arrest treatment have better neurological functioning compared to those who do not.


Eligibility criteria: Inclusion Criteria:

* All out-of-hospital cardiac arrests (OHCA) with a "shockable rhythm" (ventricular fibrillation, pulseless ventricular tachycardia) that present to the Royal Columbian Hospital. The patient may be either in active cardiac arrest with shockable rhythm or may have achieved Return of Spontaneous Circulation (ROSC).
* Over 19 years of age
* Patients requiring sedation based on the assessment of the resuscitating physician.

Exclusion Criteria:

* Any other type of cardiac arrest
* Any history of previous, pre-existing neurological deficit
* Started on Extracorporeal Membrane Oxygenation (ECMO)
* Duration of cardiac arrest without ROSC is greater than 30 consecutive minutes
* Known contraindication or hypersensitivity to ketamine
* Awake patient or no standard sedation or no intubation required
* Inability to obtain deferred consent
* Currently enrolled in any other research study involving drugs or devices
* Patients who are pregnant
* Patients who are prisoners
* Patients residing in Long Term Care (LTC) facilities

Primary outcomes:
measure: Feasibility Data
timeFrame: through study completion, an average of 6 months.
Secondary outcomes:
Other outcomes:
Locations:
city: New Westminster
country: Canada
facility: Fraser Health Authority - Royal Columbian Hospital
state: British Columbia
Study officials:
References: